Navigation Links
Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for the generic versions of Hyzaar® Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar® Tablets, 25 mg, 50 mg and 100 mg, both antihypertensives. Merck and Co. Inc.'s Hyzaar® is known generically as Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets and Merck Research Laboratories' Cozaar® is known generically as Losartan Potassium Tablets.

Losartan Potassium and HCTZ Tablets, 50 mg/12.5 mg and 100 mg/25 mg, had U.S. sales of approximately $570 million and Losartan Potassium Tablets had U.S. sales of approximately $940 million for the 12 months ending June 30, 2010, according to IMS Health. Both products are available for immediate shipment. Mylan Pharmaceuticals received final FDA approval and launched the 100 mg/12.5 mg strength of Losartan Potassium and HCTZ Tablets on April 6, 2010.

Currently, Mylan has 151 ANDAs pending FDA approval representing $92.9 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
2. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
3. Mylan Launches Generic Version of Wellbutrin XL® Tablets
4. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
5. Mylan Receives Approval for Generic Version of Prograf® Capsules
6. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
7. Mylan Announces Completion of Add-On Offering of Senior Notes
8. Mylan Announces Pricing of Add-On Offering of Senior Notes
9. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
10. Mylan Announces Settlement Agreement for Namenda®
11. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS The ... in 2017-2023. Various reasons for growth of the medical ... incidences of chronic diseases, high recovery cost of injuries ... Medical lifting sling refers to an assistive device ... These slings connect to the lift and hold the ...
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... after surgery as possible. With this in mind, SIGVARIS has created a new ... blood clot) during bed rest and provide the benefits of graduated compression when ...
(Date:12/8/2016)... Francisco, California (PRWEB) , ... December 08, 2016 , ... ... coaches, has raised an $18M Series B led by Canvas Ventures . Other ... the capital to scale its mobile platform to serve more consumers who are managing ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
(Date:12/8/2016)... AZ (PRWEB) , ... December 08, 2016 , ... ... firm with offices that serve communities in and around the greater Phoenix metropolitan ... the Homeless Youth Connection. , The mission of the Homeless Youth Connection is ...
Breaking Medicine News(10 mins):